Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Account Payables: 2020-2025

Historic Change in Account Payables for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to -$168,000.

  • Janux Therapeutics' Change in Account Payables fell 114.30% to -$168,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $867,000, marking a year-over-year increase of 146.31%. This contributed to the annual value of $1.6 million for FY2024, which is 471.84% up from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' Change in Account Payables is -$168,000, which was down 115.09% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Change in Account Payables ranged from a high of $2.6 million in Q3 2021 and a low of -$1.6 million during Q1 2025.
  • For the 3-year period, Janux Therapeutics' Change in Account Payables averaged around $106,273, with its median value being -$107,000 (2023).
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 5,642.22% in 2021, then plummeted by 326.17% in 2024.
  • Janux Therapeutics' Change in Account Payables (Quarterly) stood at -$482,000 in 2021, then skyrocketed by 146.27% to $223,000 in 2022, then skyrocketed by 46.64% to $327,000 in 2023, then spiked by 376.76% to $1.6 million in 2024, then tumbled by 114.30% to -$168,000 in 2025.
  • Its last three reported values are -$168,000 in Q3 2025, $1.1 million for Q2 2025, and -$1.6 million during Q1 2025.